THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.34]-CMP176 ID: TIP-MED-000446 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Adrenaline (Epinephrine) Tartrate IP [12.34-CMP176] — ACLS Cardiac Arrest & Vasopressor Infusion Protocol

Active Ingredient / Scientific Identity: Adrenaline • Class: Equine Hyperimmune F(ab')2 Immunoglobulin Antivenom against India's 'Big Four' Venomous Snakes

⚖️ Compare Profile
Generic / Entity NameAdrenaline (Epinephrine) Tartrate IP [Supplementary Emergency Module App-B.1] ([12.34]-CMP176)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassEquine Hyperimmune F(ab')2 Immunoglobulin Antivenom against India's 'Big Four' Venomous Sn
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustme
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Adrenaline (Epinephrine) Tartrate IP [Supplementary Emergency Module App-B.1] (TIP-MED-000446, Reference Code [12.34]-CMP176) is classified under Vaccines, Immunologicals & Emergency Toxicology Antidotes (Ch 12) as a Equine Hyperimmune F(ab')2 Immunoglobulin Antivenom against India's 'Big Four' Venomous Snakes. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-01 (Option 1A; preserved in IP_Supplementary_Emergency_Module_App_B_1.json [App-B.1]). Mandatory pre-drawn 0.5 mg IM Adrenaline 1:1000 bedside protocol prior to Polyvalent ASV infusion.
Co-indexed per approved Author Decision DEC-01 (Option 1A; preserved in IP_Supplementary_Emergency_Module_App_B_1.json [App-B.1]). Mandatory pre-drawn 0.5 mg IM Adrenaline 1:1000 bedside protocol prior to Polyvalent ASV infusion.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-01 (Option 1A; preserved in IP_Supplementary_Emergency_Module_App_B_1.json [App-B.1]). Mandatory pre-drawn 0.5 mg IM Adrenaline 1:1000 bedside protocol prior to Polyvalent ASV infusion.

4. Therapeutic Indications & Evidence-Supported Uses

  • Systemic envenomation by any of the Indian 'Big Four' venomous snakes: (1) Spectacled Cobra (Naja naja), (2) Common Krait (Bungarus caeruleus), (3) Russell's Viper (Daboia russelii), and (4) Saw-Scaled Viper (Echis carinatus)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-01 (Option 1A; preserved in IP_Supplementary_Emergency_Module_App_B_1.json [App-B.1]). Mandatory pre-drawn 0.5 mg IM Adrenaline 1:1000 bedside protocol prior to Polyvalent ASV infusion.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [12.34].
Metabolism & Biotransformation:
Renal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustment.
Elimination & Renal Adjustment:
Renal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustment.
Hepatic Impairment Considerations:
Renal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: No absolute contraindications in systemic snakebite envenomation! DO NOT perform intradermal or conjunctival ASV sensitivity skin tests (MoHFW guidelines state skin tests have zero predictive value for non-IgE anaphylactoid reactions and dangerously delay life-saving therapy). • Precautions: Early anaphylactoid/pyrogenic reactions occur in 20–50% of patients within 10–60 minutes: keep ADRENALINE (1:1000, 0.5 mg IM into anterolateral thigh) drawn up in a syringe at the bedside before starting ASV! If a reaction occurs, temporarily stop ASV, give IM Adrenaline + IV Chlorpheniramine + IV Hydrocortisone, and restart ASV slowly once BP/bronchospasm stabilises.

Key Clinical Precautions: Renal: Full ASV dose is mandatory to arrest Russell's viper venom-induced acute kidney injury and DIC. • Hepatic: No adjustment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Early anaphylactoid reaction (urticaria, pruritus, rigor/chills, fever, nausea, tachycardia), late serum sickness (fever, arthralgia, lymphadenopathy 5–14 days later).
  • Severe bronchospasm, angioedema, hypotensive anaphylactic shock.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Combine with Neostigmine (1
    • 5 mg IV/IM + Atropine 0
    • 6 mg) in neurotoxic Cobra bites (postsynaptic alpha-neurotoxin); pre-synaptic Krait beta-bungarotoxin responds poorly to Neostigmine and requires early mechanical ventilation

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.34].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Reassure patient/family that pressure-immobilisation, tourniquets, incision, suction, or herbal stones must be avoided; report delayed fever or joint pain 1-2 weeks after discharge (serum sickness).
    • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / MoHFW National Snakebite Treatment Protocol

    Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    Related Companion Monograph: See also the primary clinical reference monograph at /medicine/12-32-cmp175-adrenaline-epinephrine-tartrate-ip-supplementary-eme/ for complementary therapeutic comparison and dosing context.